Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Brandão LR, Albisetti M, Halton J, Bomgaars L, Chalmers E, Mitchell LG, Nurmeev I, Svirin P, Kuhn T, Zapletal O, Tartakovsky I, Simetzberger M, Huang F, Sun Z, Kreuzer J, Gropper S, Brueckmann M, Luciani M; DIVERSITY Study Investigators. Brandão LR, et al. Among authors: brueckmann m. Blood. 2020 Feb 13;135(7):491-504. doi: 10.1182/blood.2019000998. Blood. 2020. PMID: 31805182 Free PMC article. Clinical Trial.
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
Van de Werf F, Brueckmann M, Connolly SJ, Friedman J, Granger CB, Härtter S, Harper R, Kappetein AP, Lehr T, Mack MJ, Noack H, Eikelboom JW. Van de Werf F, et al. Among authors: brueckmann m. Am Heart J. 2012 Jun;163(6):931-937.e1. doi: 10.1016/j.ahj.2012.03.011. Am Heart J. 2012. PMID: 22709744 Clinical Trial.
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
Majeed A, Hwang HG, Connolly SJ, Eikelboom JW, Ezekowitz MD, Wallentin L, Brueckmann M, Fraessdorf M, Yusuf S, Schulman S. Majeed A, et al. Among authors: brueckmann m. Circulation. 2013 Nov 19;128(21):2325-32. doi: 10.1161/CIRCULATIONAHA.113.002332. Epub 2013 Sep 30. Circulation. 2013. PMID: 24081972 Free article. Clinical Trial.
Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Diener HC, Easton JD, Granger CB, Cronin L, Duffy C, Cotton D, Brueckmann M, Sacco RL; RE-SPECT ESUS Investigators. Diener HC, et al. Among authors: brueckmann m. Int J Stroke. 2015 Dec;10(8):1309-12. doi: 10.1111/ijs.12630. Epub 2015 Sep 30. Int J Stroke. 2015. PMID: 26420134 Clinical Trial.
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Kent AP, Pogue J, Spahr J, Clemens A, Noack H, Diener HC, Wallentin L, Yusuf S, Connolly SJ. Ezekowitz MD, et al. Among authors: brueckmann m. Europace. 2016 Jul;18(7):973-8. doi: 10.1093/europace/euv312. Epub 2016 Mar 3. Europace. 2016. PMID: 26944733 Free PMC article. Clinical Trial.
Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH; RE-DUAL PCI Steering Committee and Investigators. Cannon CP, et al. Among authors: brueckmann m. Clin Cardiol. 2016 Oct;39(10):555-564. doi: 10.1002/clc.22572. Epub 2016 Aug 26. Clin Cardiol. 2016. PMID: 27565018 Free PMC article. Clinical Trial.
205 results